Clinical Trial

A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1b, open-label, non-randomized, multicenter, dose-finding study evaluating venetoclax in combination with azacitidine in participants with treatment-naïve higher-risk MDS comprising a dose-escalation portion and a safety expansion portion.
Protocol Amendment History 3 changes
critical Trial completed 2026-08-13
notable Primary completion moved earlier: 2027-01 -> 2026-04-15 2026-08-13
minor Completion moved earlier: 2027-01 -> 2026-04-15 2026-08-13
Trial Details
NCT Number NCT02942290
Lead Sponsor AbbVie
Collaborators: Genentech, Inc.
Conditions Myelodysplastic Syndromes (MDS)
Enrollment 134 participants
Start Date 2017-01-12
Primary Completion 2026-04-15 (estimated)
Study Completion 2026-04-15 (estimated)
Updated on ClinicalTrials.gov 2026-08-12